Envestnet Asset Management Inc. Sells 262,089 Shares of Novo Nordisk A/S $NVO

Envestnet Asset Management Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,923,601 shares of the company’s stock after selling 262,089 shares during the period. Envestnet Asset Management Inc. owned 0.09% of Novo Nordisk A/S worth $217,721,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in NVO. Lockheed Martin Investment Management Co. lifted its position in Novo Nordisk A/S by 179.4% during the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after acquiring an additional 27,900 shares during the last quarter. Martin Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after purchasing an additional 41,129 shares during the period. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $1,294,000. Markel Group Inc. lifted its holdings in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares during the last quarter. Finally, WCM Investment Management LLC boosted its stake in Novo Nordisk A/S by 3.7% in the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock valued at $151,636,000 after purchasing an additional 97,477 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $43.32 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The company has a market cap of $193.40 billion, a PE ratio of 12.48 and a beta of 0.67. The company has a 50 day moving average of $53.64 and a 200-day moving average of $54.06. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 72.86%. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Analyst Ratings Changes

A number of research firms have recently weighed in on NVO. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a 2026 share‑repurchase programme (up to DKK 15bn overall; new tranche up to DKK 3.8bn) — supports capital returns and can cushion share price pressure. Novo Nordisk initiates 2026 share repurchase programme
• Neutral Sentiment: Q4 results beat estimates on revenue and EPS, showing continued obesity‑care strength — but management’s outlook (2026 sales/profit decline) is what tilted sentiment negative. NVO Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Company disclosures: annual report/SEC 20‑F filing and reported insider trading by board/executives — useful for governance context but not the primary driver of the selloff. Novo Nordisk files annual report with the SEC
• Negative Sentiment: Management warned of “painful” U.S. price cuts and issued a weak 2026 guidance range (sales and operating profit expected to fall), which triggered the earlier large drop and remains the main reason investors are selling. Novo Nordisk’s shock 2026 guidance points to obesity battle heating up
• Negative Sentiment: Hims & Hers began offering a compounded Wegovy pill at ~$49 and Novo threatened legal action — the move stokes fears about durable pricing pressure, compounding competition and margin erosion. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
• Negative Sentiment: Market competition and execution gaps: Eli Lilly’s stronger guidance and manufacturing scale are shifting investor preference away from Novo, amplifying downside risk for NVO. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Negative Sentiment: Sales pressure in China: Novo reported its first Ozempic sales decline in the greater China region, which signals geographic headwinds beyond the U.S. pricing story. Novo reports first Ozempic sales drop in greater China region

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.